Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7875913 in Healthy Volunteers and in Combination With Cevostamab in Relapsed/Refractory Multiple Myeloma
NCT07342114Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Mar 2026
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of RO7875913 in multiple myeloma (MM) (3 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants with Adverse Events at 2 years. Started Mar 2026; status: active, not recruiting.
02
Drugs
RO7875913
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07342114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342114.